Company: CI
Filing Date: 2025-09-02
Form Type: 424B5
Source: 0001140361-25-033574
Chunk: 9

Company: Cigna Group
Filing Date: 2025-09-02
Form: 424B5
Chunk 9
---
 our property or assets as, or substantially as, an entirety to any person. These covenants are subject to important qualifications and limitations. See “Description of Debt Securities—Limitations on Liens on Common Stock of Designated Subsidiaries” and “Description of Debt Securities—Consolidation, Merger and Sale of Assets” in the accompanying prospectus.

#### Minimum Denominations
**The Notes will be issued and may be transferred only in minimum denominations of $2,000 and multiples of $1,000 in excess thereof.

Material United States Federal Income Tax Consequences

For a summary of certain United States federal income tax consequences of the purchase, ownership and disposition of the Notes, see “Material United States Federal Income Tax Consequences.”**

#### Risk Factors
For a discussion of factors you should carefully consider before deciding to purchase the Notes, see “Cautionary Note Regarding Forward-Looking Statements and Risk Factors” in this prospectus supplement and the “Risk Factors” discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, incorporated by reference in this prospectus supplement and the accompanying prospectus.

#### Conflicts of Interest
As described under “Use of Proceeds,” we intend to use a portion of the net proceeds from this offering to fund repayment of the Term

<div align='center'>S-3</div>

#### TABLE OF CONTENTS
Loan Facility. Certain of the underwriters or their affiliates are lenders under the Term Loan Facility. As a result, such underwriters or their affiliates may receive 5% or more of the net proceeds from this offering. Such underwriters would be deemed to have a conflict of interest within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (“FINRA Rule 5121”). Accordingly, this offering is being made in compliance with the requirements of FINRA Rule 5121. See “Use of Proceeds” and “Underwriting (Conflicts of Interest)” for additional information.

<div align='center'>S-4</div>

TABLE OF CONTENTS

SELECTED FINANCIAL INFORMATION The following table presents selected historical consolidated financial information of The Cigna Group. The selected historical consolidated financial information of The Cigna Group for the six-month period ended June 30, 2025 and each of the years ended December 31, 2024 and 2023, and as of December 31, 2024 and December 31, 2023,